A once-in-a-decade chance to get rich by investing in FTSE 100 shares?

After lagging overseas stocks for over 10 years, our writer investigates whether FTSE 100 shares could be the smart place for his money today.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 index has attracted its fair share of criticism in recent years. Arguably, much of the flak has been warranted.

Recent research from Goldman Sachs has revealed that the Footsie delivered a 6% total annual return over the past decade. Compared to 8% for Europe’s Stoxx 50 and 13% for America’s S&P 500, Britain’s largest shares have been international laggards.

However, there are indications the tide could be turning for FTSE 100 stocks. Consequently, UK investors might consider looking closer to home for strong future returns. Here’s why.

A rare bargain opportunity

Using the 12-month forward price-to-earnings (P/E) ratio as a gauge, FTSE 100 shares look remarkably cheap relative to pricier stocks stateside.

UK shares trade at a 55% discount to their US counterparts. This gap is the widest it’s been since 1988 by a considerable margin. Value investors have good reasons to view today as a potential buying opportunity we haven’t seen for many, many years.

However, as a note of caution, this gulf has widened substantially since the 2016 Brexit vote and shows little sign of narrowing. At least for now.

Worryingly, UK-focused equity funds have suffered retail investor outflows for three years on the trot. There’s a risk Britain’s stock market malaise could continue for a while yet. Restoring investor confidence is far from guaranteed.

The stagnation of Japanese stocks for 30 years, starting in the early 1990s, is evidence of how long the suffering can persist in developed equity markets.

Where next for UK shares?

That said, the comparison with Japan only goes so far. Its ‘Lost Decades’ followed the bursting of a huge asset price bubble amid periods of monetary tightening.

By contrast, the UK seems to be heading in the other direction today. Despite holding interest rates at 5% in the last Monetary Policy Committee meeting, the Bank of England indicated it’s on a trajectory towards further easing over the coming months.

Governor Andrew Bailey said interest rates are “now gradually on the path down“. Additional rate cuts could spark some much-needed growth for FTSE 100 share prices.

In this context, I can see the logic behind the latest Goldman Sachs FTSE 100 forecast. The bank predicts the index will surge to 8,800 points within 12 months. As I write, the Footsie’s hovering around the 8,233 level.

A FTSE 100 stock to consider

Identifying which shares in the index appear deeply undervalued can be very lucrative over the long run. One candidate to consider buying is pharma giant GSK (LSE:GSK).

The stock’s forward P/E of 8.64 is well below the average for other companies in the industry and the index as a whole.

GSK also stacks up well on other valuation metrics. A price-to-book (P/B) ratio of 4.4 and price-to-sales (P/S) ratio of 1.8 both indicate a potential bargain.

Granted, long-running litigation concerning the firm’s Zantac heartburn medication continues to cloud the growth outlook. Disappointing sales for the company’s shingles and respiratory syncytial virus (RSV) vaccines are also a cause for concern.

But, I’m pleased to see other areas of the business, including cancer, HIV, and other speciality medicines, are growing fast. The group’s overall revenue performance exceeded expectations in Q2 and FY24 guidance has been upgraded.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Charlie Carman has positions in Goldman Sachs Group and GSK. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Older couple walking in park
Investing Articles

No savings at 50? Here are the stocks I’d buy to aim for a £4,037 second income in retirement

With 15 years to retirement, it’s not too late to start investing for a second income. Stephen Wright outlines how…

Read more »

Mature black couple enjoying shopping together in UK high street
Investing Articles

How investing just £6.86 a day could make me a Stocks and Shares ISA millionaire 

Harvey Jones discovers that drip-feeding small, regular sums into a Stocks and Shares ISA can deliver a stunning total return,…

Read more »

Environmental technology concept.
Investing Articles

Nuclear ambitions: the mini power plants keeping the Rolls-Royce share price up

Can a new nuclear deal keep the Rolls-Royce share price heading to the skies? Our writer looks at the factors…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£9,000 in savings? Here’s how I’d aim to turn that into £684 a month in passive income!

Money put in high-dividend-paying stocks with the returns used to buy more shares can transform small investments into big passive…

Read more »

Investing Articles

If I’d put £20,000 into the FTSE 100 at the start of 2024, here’s what I’d have now

This investor takes a look at the stark difference in performance between the FTSE 100 and S&P 500 indexes so…

Read more »

Investing Articles

2 FTSE 100 shares I’d buy hand over fist today!

This Fool's on the hunt for FTSE 100 shares. If he had the cash, he'd rush to buy these two…

Read more »

Investing Articles

What’s going on with the IAG share price? It’s on a roll

The IAG share price has surged 25% over the past six months, with most of that growth coming in the…

Read more »

Investing Articles

I’m thinking of buying these cheap passive income stocks right now

I'm searching for passive income stocks for my 2024 Stocks and Shares ISA. The big problem? There are too many…

Read more »